Drug Trial Radar · NCT05531565
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Sep 13, 2022
Primary completion
Oct 20, 2026
Study completion Dec 14, 2027
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Sep 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the skin disease. Researchers will measure symptoms and signs of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI). The main questions researchers want to answer are: * How many participants have a score of 0 or 1 on the CLA-IGA-R looking at skin redness after treatment? * How many participants have their skin disease activity go down by at least 70% as measured by CLASI? Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and CLE have on the quality of life of participants using a group of questionnaires. The study will be split into 2 parts - Part A and Part B. Both parts will be done as follows: * After screening, participants will be randomized to receive either litifilimab or placebo for the 1st treatment period. A placebo looks like the study drug but contains no real medicine. * Participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks. * The 1st treatment period will be double blinded which means neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo. * This double blinded treatment period will last 24 weeks, after which the 2nd treatment period will begin. * During the 2nd treatment period, all participants will receive litifilimab for 28 weeks. * After completing treatment in this study, participants that qualify will be given the choice to join the Long-Term Extension study, 230LE305. If they do not, they will move into a follow-up safety period that will last up to 24 weeks. * The total study duration for participants will be up to 80 weeks.
Conditions
- Subacute Cutaneous Lupus Erythematosus
- Chronic Cutaneous Lupus Erythematosus
Interventions
LitifilimabDrug
Administered as specified in the treatment arm.
PlaceboDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A: Percentage of Participants who Achieve a Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1Time frame: Week 16
- Part B: Percentage of Participants who Achieve Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity Score (CLASI-70) Response, Defined as ≥ 70% Decrease in CLASI-A Score From BaselineTime frame: Baseline to Week 24
Locations
315 sites in 30 countries. Site status is shown where the registry gives one.
Pinnacle Research Group, LLC
Anniston, Alabama
UAB Center for Women's Reproductive Health
Birmingham, Alabama
Arizona Arthritis & Rheumatology Research, PLLC
Phoenix, Arizona
The Regents of the University of California
La Jolla, California
Dermatology Research Associates
Los Angeles, California
Clinical Science Institute
Santa Monica, California
Inland Rheumatology Clinical Trials, Inc.
Upland, California
Denver Arthritis Clinic
Denver, Colorado
Omega Research Debary, LLC
DeBary, Florida
Centre for Rheumatology, Immunology and Arthritis
Fort Lauderdale, Florida
University of Florida
Gainesville, Florida
University of Miami Miller School of Medicine
Miami, Florida
Millennium Medical Research, LLC
Miami, Florida
Medical Research Center of Miami
Miami, Florida
Diverse Clinical Research LLC
Miami, Florida
Charisma Medical and Research Center
Miami Lakes, Florida
Leading Edge Dermatology
Plantation, Florida
Augusta University
Augusta, Georgia
Rush University Medical Center
Chicago, Illinois
OrthoIllinois
Rockford, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Equity Medical
Bowling Green, Kentucky
LSU Health Sciences Center Shreveport
New Orleans, Louisiana
Tufts Medical Center
Boston, Massachusetts
Brigham And Women's Hospital
Boston, Massachusetts
Essential Dermatology
Natick, Massachusetts
Beacon Clinical Research, LLC
Quincy, Massachusetts
University of Massachusetts, Worcester
Worcester, Massachusetts
David Fivenson, MD, Dermatology, PLLC
Ann Arbor, Michigan
Oakland Hills Dermatology
Auburn Hills, Michigan
AA MRC LLC Ahmed Arif Medical Research Center
Flint, Michigan
Revival Research Institute, LLC
Troy, Michigan
Saint Louis University
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Albuquerque Center For Rheumatology
Albuquerque, New Mexico
University of New Mexico School of Medicine
Albuquerque, New Mexico
NYU Langone Brooklyn
Brooklyn, New York
Universal Dermatology, PLLC
Fairport, New York
Northwell Health, Inc. PRIME
Great Neck, New York
Columbia University Medical center
New York, New York
Showing 40 of 315 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.